Table 2.
Breast cancer-related parameters of the study (IORT) and control collective (non-IORT)
| Variable |
With IORT (n = 39) frequency (%) |
Without IORT (n = 55) frequency (%) |
p-value |
|---|---|---|---|
| Localization of breast cancer/surgery | 0.4304 | ||
| Left | 28 (71.8) | 33 (60) | |
| Right | 11 (28.2) | 21 (38.2) | |
| Both sides | 0 (0) | 1 (1.8) | |
| TNM status | 0.0117 | ||
| ypT0 | 2 (5.1) | 1 (1.8) | |
| pT1a | 6 (15.4) | 3 (5.5) | |
| pT1b | 6 (15.4) | 4 (7.3) | |
| pT1c | 17 (43.6) | 28 (50.9) | |
| pT2 | 8 (20.5) | 17 (30.9) | |
| pT3 | 0 (0) | 1 (1.8) | |
| pT4 | 0 (0) | 1 (1.8) | |
| pN0 | 31 (79.5) | 42 (76.4) | 1.000 |
| pN1 | 8 (20.5) | 12 (21.8) | |
| pN2 | 0 (0) | 1 (1.8) | |
| cM0 | 20 (51.3) | 29 (52.7) | 1.000 |
| M1 | 1 (2.6) | 1 (1.8) | |
| Mx | 18 (46.2) | 25 (45.5) | |
| ER positive | 32 (82.1) | 50 (90.9) | 0.2259 |
| PR positive | 30 (76.9) | 46 (83.6) | 0.4151 |
| Her2 positive | 4 (10.3) | 7 (12.7) | 1.000 |
| Neoadjuvant chemotherapy | 2 (5.1) | 1 (1.8) | n.a. |
ER estrogen receptor, PR progesterone receptor, IORT intraoperative radiotherapy